Navigation Links
Uroplasty Reports Results for Second Quarter FY2010
Date:11/2/2009

MINNEAPOLIS, Nov. 2 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the second fiscal quarter ended September 30, 2009.

"Our team continues to execute our strategy for the current fiscal year by growing U.S. Macroplastique sales and maximizing the potential for gaining a unique CPT code for Urgent PC® treatments," said David Kaysen, President & CEO. "During the quarter, we learned that a manuscript of the results from the SUmiT Trial has been recommended for publication in The Journal of Urology® and is tentatively scheduled to appear in the April 2010 issue. This study reports on a 220-subject, multicenter, randomized, controlled clinical trial designed to directly compare the effectiveness of PTNS using Urgent PC to a validated sham intervention over a 12-week period and is a major component of our strategy to expand and support third-party reimbursement coverage of Urgent PC treatments. The investigators' submission of this manuscript was ahead of the original timetable. We fully anticipate submitting an application to the American Medical Association (AMA) for a unique CPT code for PTNS prior to the November 11, 2009 deadline.

"While our fiscal second quarter and first half financial performance is below year-ago results, we are encouraged by the continued strong growth of our U.S. Macroplastique product sales," continued Mr. Kaysen. "Sales of our Macroplastique product in the U.S. through six months of our current fiscal year have about doubled in each quarter over the corresponding year-ago quarter. At the same time, Urgent PC sales in the U.S., while continuing to be challenged by the uncertain insurance reimbursement e
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
2. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
3. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
4. Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... therapy (SBRT) can eliminate the targeted tumor while ... for patients with inoperable non-small cell lung cancer, ... Oncology Group study published in the March 17 ... American Medical Association . Stereotactic body radiation therapy ...
... Mellon University will host "Invention to Venture," a one-day ... interested in learning about what it takes to launch ... wide range of topics including entrepreneurship, intellectual property issues ... professor of engineering and public policy at Carnegie Mellon ...
... , ,New Rochelle, NY, March 16, 2010Announcing the ... dynamic new application delivering the latest news, resources, ... your iPhone. Convenient access to information across the ... environmental, and public health fields is available with ...
... ... ... is launching its new Prodigy Count-a-dose™ April 1, a precise and safe syringe-filling device for ... device which can easily measure and mix two insulins at one time. The device had ...
... ... way to fix, remodel or build a home will be released today. This new concept protects ... fraud, poor home construction, poor health from a sick home, and legal problems relating to the ... (PRWEB) March 16, 2010 -- ...
... study puts cost per life-year gained at about $66,200 ... chemotherapy agents for metastatic colon cancer improve patient survival ... at Emory University in Atlanta analyzed data from 4,665 ... cancer between 1995 and 2005. Compared to those who ...
Cached Medicine News:Health News:SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients 2Health News:SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients 3Health News:Prodigy Re-Launches Syringe-Filling System for Blind and Low-Vision Diabetics 2Health News:Stop Ripping Me Off! Is the Title of a New Consumer Protection Book Being Released Today 2Health News:Stop Ripping Me Off! Is the Title of a New Consumer Protection Book Being Released Today 3Health News:Are New Chemo Treatments Cost-Effective? 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: